Tom Huang
Meta (United States)(US)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, Immune cells in cancer, Immune Cell Function and Interaction, Acute Myeloid Leukemia Research, HIV/AIDS drug development and treatment
Most-Cited Works
- → Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production(2020)42 cited
- → Investigation of collision‐induced dissociations involving odd‐electron ion formation under positive electrospray ionization conditions using accurate mass(2010)34 cited
- → CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy(2022)12 cited
- → ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell–mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models(2022)9 cited
- → Application of Dbs Sampling in Combination With Lc–MS/MS For Pharmacokinetic Evaluation of A Compound With Species-Specific Blood-To-Plasma Partitioning(2012)8 cited
- → Abstract 1023: CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cells activation(2020)4 cited
- → Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor(2023)2 cited
- → Abstract 2594: Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor(2022)2 cited
- → Abstract 1037: Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production(2020)1 cited
- → Supplementary Methods from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor(2023)